Trial Profile

A Phase 1/2 Open-label Dose-escalation Study to Evaluate the Safety, Tolerability, and Biological Activity of EPI-321, an AAVrh74-delivered Epigenetic Editing Therapy in Adult FSHD Patients

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 24 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EPIC 321 (Primary)
Indications Facioscapulohumeral muscular dystrophy
Focus Adverse reactions; First in man
Sponsors EPIC BIO; Epicrispr Biotechnologies

Most Recent Events

20 Jul 2026 Planned primary completion date changed from 31 Mar 2031 to 7 Jul 2027.
07 Jul 2026 Status changed from recruiting to active, no longer recruiting.
07 Jul 2026 According to an Epicrispr Biotechnologies media release, additional clinical data from the study are expected to be presented at the World Muscle Society Annual Congress in September 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com